Clinical Trials on 乳腺癌,男性 in United Kingdom
总计27159个结果
-
University of WashingtonNational Cancer Institute (NCI)终止
-
National Cancer Institute (NCI)终止
-
University of WashingtonNational Cancer Institute (NCI)撤销
-
National Cancer Institute (NCI)完全的
-
University of WashingtonNational Cancer Institute (NCI)完全的
-
National Cancer Institute (NCI)完全的
-
National Cancer Institute (NCI)完全的
-
University of WashingtonNational Cancer Institute (NCI)完全的
-
Mayo ClinicMarker Therapeutics, Inc.完全的HER2阳性乳腺癌 | 男性乳腺癌 | II期乳腺癌 | IIIA期乳腺癌 | IIIB期乳腺癌 | IIIC期乳腺癌美国
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Celgene Corporation终止
-
University of WashingtonNational Cancer Institute (NCI)完全的
-
National Cancer Institute (NCI)完全的
-
University of WashingtonNational Cancer Institute (NCI)完全的
-
University of WashingtonNational Cancer Institute (NCI)终止
-
National Cancer Institute (NCI)完全的
-
National Cancer Institute (NCI)终止
-
Wake Forest University Health SciencesMerck Sharp & Dohme LLC完全的
-
University of Chicago完全的
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI); Synta Pharmaceuticals Corp.; New York University Cancer Institute完全的HER2阳性乳腺癌 | 男性乳腺癌 | IV 期乳腺癌 | IIIA期乳腺癌 | IIIB期乳腺癌 | IIIC期乳腺癌 | 复发性乳腺癌美国
-
National Cancer Institute (NCI)完全的
-
University of WashingtonNational Cancer Institute (NCI)完全的HER2阳性乳腺癌 | 男性乳腺癌 | IV 期乳腺癌 | II期乳腺癌 | IIIA期乳腺癌 | IIIB期乳腺癌 | IIIC期乳腺癌 | 复发性乳腺癌美国
-
National Cancer Institute (NCI)完全的男性乳腺癌 | IV 期乳腺癌 | IIIB期乳腺癌 | IIIC期乳腺癌 | 复发性乳腺癌 | 雌激素受体阴性乳腺癌 | 孕激素受体阴性乳腺癌美国
-
University of WashingtonNational Cancer Institute (NCI)完全的
-
National Cancer Institute (NCI)完全的男性乳腺癌 | IV 期乳腺癌 | IIIB期乳腺癌 | IIIC期乳腺癌美国
-
University of Southern CaliforniaNational Cancer Institute (NCI)终止男性乳腺癌 | IV 期乳腺癌 | II期乳腺癌 | IIIA期乳腺癌 | IIIB期乳腺癌 | IA期乳腺癌 | IB 期乳腺癌 | IIIC期乳腺癌 | 复发性乳腺癌美国
-
University of WashingtonNational Cancer Institute (NCI)完全的
-
Stanford UniversityNational Cancer Institute (NCI)终止
-
H. Lee Moffitt Cancer Center and Research InstituteNational Cancer Institute (NCI)完全的
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)完全的炎性乳腺癌 | 男性乳腺癌 | IV 期乳腺癌 | IIIB期乳腺癌 | 雌激素受体阴性乳腺癌 | 雌激素受体阳性乳腺癌 | 孕激素受体阴性乳腺癌 | 孕激素受体阳性乳腺癌美国
-
University of WashingtonNational Cancer Institute (NCI)完全的炎性乳腺癌 | 男性乳腺癌 | II期乳腺癌 | IIIA期乳腺癌 | IIIB期乳腺癌 | IIIC期乳腺癌美国
-
University of ArizonaNational Cancer Institute (NCI); GlaxoSmithKline终止男性乳腺癌 | II期乳腺癌 | IIIA期乳腺癌 | IIIB期乳腺癌 | 复发性乳腺癌 | 雌激素受体阳性乳腺癌 | 人类表皮生长因子 2 阴性乳腺癌美国
-
Jose Pablo LeoneEli Lilly and Company; Translational Breast Cancer Research Consortium (TBCRC)招聘中
-
National Cancer Institute (NCI)完全的未明确的成人实体瘤,特定方案 | HER2阳性乳腺癌 | 男性乳腺癌 | IV 期乳腺癌 | IIIB期乳腺癌 | IIIC期乳腺癌 | 复发性乳腺癌美国
-
University of ArizonaNational Cancer Institute (NCI)完全的
-
University of WashingtonNational Cancer Institute (NCI)完全的
-
Northwestern UniversityEisai Inc.未知男性乳腺癌 | II期乳腺癌 | IIIA期乳腺癌 | IIIB期乳腺癌 | 三阴性乳腺癌 | IA期乳腺癌 | IB 期乳腺癌 | IIIC期乳腺癌 | 雌激素受体阴性乳腺癌 | 孕激素受体阴性乳腺癌 | HER2 阴性乳腺癌美国
-
H. Lee Moffitt Cancer Center and Research InstituteHorizon Pharma Ireland, Ltd., Dublin Ireland完全的
-
Innocrin Pharmaceutical完全的乳腺癌 | 晚期乳腺癌 | 转移性乳腺癌 | 三阴性乳腺癌 | 男性乳腺癌 | ER+乳腺癌 | 乳腺癌美国
-
University of WashingtonNational Cancer Institute (NCI)完全的
-
H. Lee Moffitt Cancer Center and Research InstituteUnited States Department of Defense主动,不招人乳腺癌 | 乳腺癌,男性 | HER2阳性乳腺癌 | 浸润性乳腺癌 | II期乳腺癌 | 乳腺癌女性 | HER2阳性乳腺癌 | III期乳腺癌美国